ESG Report

Overview

The report describes DFE Pharma's 2023 ESG progress, including its first double materiality assessment in preparation for CSRD and its company-wide near-term emissions targets submitted to SBTi. It reports 2023 Scope 1, Scope 2, and Scope 3 emissions of 6,601, 5,340, and 952,189 ton CO2 eq., respectively. The company also reports 450 employees, 25% women in the workforce, and a Silver EcoVadis rating placing it among the leading performers in its sector.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2023
Period: 1 January 2023 – 31 December 2023
Language: English
Pages
File size
Restatement: Disclosed

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

GRI level
SBTi status

Materiality

Assessment
Basis
Matrix

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services